Whether a reduction in serum FGF21 and, in effect, the prevention of FGF21 resistance in patients with NASH lowers the risk of future cardiovascular disease events remains unknown but of great significance given that cardiovascular disease is a leading cause of morbidity and mortality in patients with NAFLD and NASH [2]. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.